Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

Inclusion criteria

for those with hepatic impairment:

• Physical signs consistent with a clinical diagnosis of liver cirrhosis
• Child-Pugh Clinical Assessment Score consistent with degree of hepatic impairment
• Otherwise considered healthy

Inclusion criteria

for healthy volunteers:

• In good health.

Exclusion criteria

for those with hepatic impairment:

• Clinically significant abnormal findings other than hepatic impairment
• Clinical evidence of severe ascites
• History of surgical portosystemic shunt
• Any evidence of progressive liver disease within the last 4 weeks

Exclusion criteria

for healthy controls:

• Clinical evidence of liver disease or liver injury
• A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result
• Use of any prescription medication within 1 month prior to dosing

Other protocol defined inclusion/exclusion criteria may apply.